CLINICAL DIFFERENTIATION AND MODERN METHODS OF TREATMENT OF VITILIGO IN ADULTS AND CHILDREN
Abstract
Vitiligo is a chronic autoimmune skin disorder characterized by the destruction of melanin-producing cells, resulting in white patches on the skin. The condition affects approximately 1% of the global population, with approximately 50% of cases occurring in individuals under the age of 20 (Ezzedine et al., 2012). The clinical presentation of vitiligo can be diverse, and the treatment approach varies depending on the severity, location, and extent of the lesions. This article aims to discuss the clinical differentiation and modern methods of treatment of vitiligo in adults and children.
Keywords
Vitiligo, skin disorders, diagnoses, researches, modern treatments, dermatology, children.
References
- Ezzedine, K., et al. (2012). Vitiligo: a comprehensive review. Journal of the American Academy of Dermatology, 67(5), 860-876.
- Sheth, V. M., et al. (2014). Vitiligo: pathogenesis, clinical features, and diagnosis. Journal of Clinical and Aesthetic Dermatology, 7(10), 14–25.
- Huff SB, Gottwald LD. Repigmentation of tenacious vitiligo on apremilast. Case Rep Dermatol Med. 2017;2017(2386234) doi: 10.1155/2017/2386234.
- Craiglow BG, King BA. Tofacitinib citrate for the treatment of vitiligo: A pathogenesis-directed therapy. JAMA Dermatol. 2015; 151:1110–1112. Doi: 10.1001/jamadermatol.2015.1520.
- Komnitski M, Komnitski A, Komnitski Junior A, Silva de Castro CC. Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation. A Bras Dermatol. 2020; 95:473–476. Doi: 10.1016/j.abd.2019.08.032.
- Scheinberg M, Ferreira SB, Santos DDCB. Tofacitinib-induced remission simultaneously in arthritis and vitiligo. Eur J Rheumatol. 2021; 8:55–56. Doi: 10.5152/eurjrheum.2020.20007.
Downloads
Download data is not yet available.